Letter Urging Congress to Reject All Proposals to Cut Medicaid
TAG was proud to sign on to this 2/3/25 letter created by HIV Health Care Access Working Group (HHCAWG) of the Federal AIDS Policy Partnership (FAPP).
TAGline November 2024
This year’s edition of TAGline takes stock of the state of the HIV, TB, and HCV pandemics worldwide, and advances bold visions for what a future without them must look like.
2024 TAG Update
As we approach the end of 2024, we want to share with you some of the remarkable progress we’ve made together, and you'll see some of our work in the 2024 TAG Update.
TAG Statement on the Global Fund and Other Funding Sources to Fight TB, HIV, and Other Pandemics
In advance of the 52nd Meeting of the Board of the Global Fund to Fight AIDS, Tuberculosis, and Malaria (the Global Fund) and the 2024 Union World Conference on Lung Health, Treatment Action Group (TAG) releases this statement in response to ongoing conversations about the Global Fund’s program allocations for HIV, tuberculosis (TB), and malaria.
Gilead Deal to Expand Access to Lenacapavir for PrEP Falls Short
TAG recognizes Gilead Science’s announcement that it has issued six voluntary licenses to produce generic lenacapavir for distribution within 120 high HIV burden countries as a first step toward broadening access to this potent preventive drug for millions of people at risk of HIV.
Statement on the UN High Level Meeting on Antimicrobial Resistance Final Draft Political Declaration
Treatment Action Group (TAG) congratulates Malta and Barbados, co-facilitators, and all United Nations (UN) Member States participating in the High-Level Meeting on Antimicrobial Resistance (AMR) upon the publication of the final draft of the Political Declaration.
2024 Pipeline Report
Pipeline Report provides an overview of research and provides an overview of research and development of innovations for diagnosing, preventing, treating, and curing HIV, hepatitis C virus (HCV), and tuberculosis (TB).
2023 Annual Report
We're pleased to share with you our latest Annual Report, which highlights everything we accomplished in 2023.
Treatment Action Group Statement on Lenacapavir PrEP: Getting from Efficacy to Access Requires Generic Licensing and Cost Reductions
Treatment Action Group (TAG) welcomes the news that the long-acting injectable HIV capsid inhibitor lenacapavir has proven efficacious at preventing HIV acquisition among young women and adolescent girls in South Africa and Uganda.
Treatment Action Group Calls on NY City Council to Override and Mayor Adams to Reverse Egregious Cuts to New York City HIV Funding
In response to disheartening news of the proposed $5.3 million cut in HIV/AIDS funding by the Adams administration, we at Treatment Action Group (TAG) express our resolute opposition, in solidarity with our partner organizations that would be harmed by the egregious, unconscionable cuts to HIV services and programs in New York City.